Get notified of page updates

RAD51C Gene Mutations: Cancer Risk

People with an inherited mutation in the RAD51D gene have an increased risk for certain types of cancer. Learn about these risks. Stay up to date by signing up for our community newsletter.

Glossary on

off

Cancer Risks Associated with an Inherited Mutation

If you have tested positive for a mutation, we recommend consulting with a genetics expert who can assess your personal and family history of cancer and can help you decide on a plan to manage your risk.

Experts at the National Comprehensive Cancer Network (NCCN) created guidelines which estimate the cancer risks for people with mutations. These cancer risk estimates are updated based on the latest research. The risks listed below are based on the 2026 NCCN guidelines.

It is important to note that cancer risks are estimates over the course of a person's lifetime. Your lifetime risk and risk over the next five years will vary depending on:

current age
gender
specific mutation
personal and family health history
diet, exercise, lifestyle and other factors

Breast cancer

Women with a mutation have about a 20% lifetime risk for breast cancer. Women in the general population have about a 12.5% risk.
More research is needed to understand the risk for a new breast cancer diagnosis in women with mutations who have had breast cancer and have not had double mastectomies. Some data suggests that the risk for a new breast cancer diagnosis within 10 years is very low (less than 2%) - similar to women without a mutation.

Ovarian, and primary peritoneal cancer

Women with a mutation have about a 10-15% lifetime risk for ovarian, or primary peritoneal cancer (these three cancers and their risks are related and are often referred to together as ovarian cancer). This compares with a 1.3% risk for women in the general population.

Other cancer risks for people with a mutation

There is not yet enough research to conclude that a mutation is associated with an increased risk of other cancers. However, there is a approved for treating prostate cancer in people with a mutation found in their tumor. Research on the risk for cancer in people with mutations is ongoing.